Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 249

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Osteoporosis in Men

Bilezikian, J. P. · 1999 · Journal of Clinical Endocrinology & Metabolism

Abstract

Osteoporosis has received increasing attention as one of the major disorders of our time. With over 20 million women at risk for fracture, and over 1 million fractures occurring annually, the importance of this disease cannot be overstated. The health care bill attributed to osteoporosis is well over 20 billion dollars. Moreover, fractures associated with osteoporosis, especially hip fracture, can lead to devastating effects on the quality of life, with many individuals unable to resume their former life style and requiring ongoing assistance thereafter. Thus, the table is set for a major thrust on this disease. Pharmaceutical companies are investing untold resources in the search for therapies, foundations are spreading the word among the public, and funding agencies such as the NIH are committed to an investigative agenda to gain key insights into bone biology and mechanisms associated with bone loss. This good news augurs well for the future. Typical of our gender-oriented focus upon many diseases, however, the spotlight on osteoporosis has been on women, simply because women are much more likely to develop osteoporosis than men. This relative exclusivity has delayed progress in understanding the counterpart syndrome, osteoporosis in men. However, osteoporosis in men is not rare, nor are its consequences (1). This state of affairs is reminiscent of a decade ago when heart disease was considered to be primarily a disorder of males. With very little attention given to heart disease in women, it was also mistakenly assumed that what would be learned about male heart disease would automatically apply to female heart disease. Such erroneous assumptions have also been made in the field of osteoporosis; what we know about the female skeleton is often uncritically applied to the male skeleton. Alternatively, and also incorrect, what we know about the female skeleton has been regarded by some as nonoperative in men, simply because men with osteoporosis present differently. Nevertheless, despite the pace, we are slowly learning about osteoporosis in men. It clearly is a pervasive disorder and in a number of respects is different from the disease in women. The purpose of this commentary is to place the available information about male osteoporosis into a practical and informative perspective. The number of men afflicted with osteoporosis is unknown. If one uses fracture as a clear end point, estimates of lifetime risk range from 13–25% (1). This is lower than estimates for Caucasian women, in whom lifetime fracture risk approaches 50%. The diagnosis of osteoporosis, however, no longer depends upon the end result of the disease process. The advent of quantitative imaging technology has allowed us to discover the population at risk before fractures occur. For men and women, fracture risk is directly related to bone mass. Using the WHO guidelines, osteoporosis is present if bone mineral density (BMD) is more than 2.5 sd below the peak bone mass reference standard for young women. When this criterion is applied to women in the United States, 4–6 million women have osteoporosis, and an additional 13–17 million women have osteopenia (BMD between 1–2.5 sd below peak bone mass). The respective age-adjusted prevalence figures are 18% and 50%. If one uses the same criterion for men, namely 2.5 sd below the peak bone mass reference standard for young men, 1–2 million men have osteoporosis, and another 8–13 million have osteopenia. The respective age-adjusted prevalence figures are 6% and 47%. It is not clear, however, whether the same cut-off values should be used, because men achieve more peak bone mass than women and have larger bones, two points that could argue that for the same percent reduction from the gender-based reference standard there would be fewer fractures in men. On the other hand, if one applies the female reference standard to men (2.5 sd below peak bone mass for women), the numbers become much smaller, namely 0.3–1 million men with osteoporosis (age-adjusted prevalence, 4%) and 4–9 million with osteopenia (age-adjusted prevalence, 33%). In either event, the proportion of men with osteoporosis or reduced bone mass relative to the entire population is substantial. Another key factor that tends to keep incidence figures below those for women is that men tend to develop osteoporosis later in life, by about a decade. As the male life span is shorter than the female life span, it has been quipped that men do not live long enough to sustain the complications of osteoporosis. For the same reason, however, namely that complications occur later in life, when men do sustain a hip fracture, associated mortality figures tend to be much higher than those in women. However the incidence figures and diagnostic criteria are viewed, it is true that men in western countries are less likely to develop osteoporosis than women. Men achieve greater peak bone mass than women, by about 8–10%, when areal density is measured. A large

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.84.10.3431

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 249

Metadata

Authors
Bilezikian, J. P.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1999-10-01
Volume
84
Issue
10
Pages
3431-3434
ISSN
0021-972X (ISSN-L)
OpenAlex
W3022800007
Cited by
249
References
5
FWCI
10.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osteoporosis in Men. https://app.cochat.ai/papers/10.1210/jc.84.10.3431
The paper
Bilezikian, J. P. (1999). Osteoporosis in Men. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.10.3431

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.